Proteus penneri;Proteus penneri

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 24, Issue SUPPL.1, 2006, Pages 8-13

  Cantón, Rafael ^a   Sánchez Moreno, M Paz ^b   Reilly, María Isabel Morosini ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b Laboratorio Regional de Salud Publica   (Spain)

Author keywords

Antimicrobial resistance; Microbiology; Proteus penneri

Indexed keywords

AMINOPENICILLIN; AZTREONAM; BETA LACTAMASE; CEFOTAXIME; CEFTAZIDIME; CEFUROXIME; CEPHALOSPORIN; CLAVULANIC ACID;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM IDENTIFICATION; BLOOD CULTURE; EVOLUTIONARY HOMOLOGY; GENE CONTROL; GENE MUTATION; NONHUMAN; PHENOTYPE; PROTEUS MIRABILIS; PROTEUS PENNERI; PROTEUS VULGARIS; URINE;

DRUG RESISTANCE, MICROBIAL; HUMANS; PROTEUS INFECTIONS; PROTEUS PENNERI;

EID: 34548714610     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1157/13094272     Document Type: Article

References (25)

1. Hickman FW, Steigerwalt AG, Farmer JJ III, Brenner DJ. Identification of Proteus penneri sp. nov., formerly known as Proteus vulgaris indole negative or as Proteus vulgaris biogroup 1. J Clin Microbiol. 1982;15:1097-102.
2. Abbott SL. Klebsiella, Enterobacter, Citrobacter, Serratia, Plesiomonas, and other Enterobacteriaceae. En: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH, editors. Manual of clinical microbiology. 8th ed. Washington: American Society for Microbiology; 2003. p. 684-700.
3. Janda JM, Abbott SL, Khashe S, Probert W. Biochemical identification and characterization of DNA groups within the Proteus vulgaris complex. J Clin Microbiol. 2001;39:1231-4.
4. O'Hara CM, Brenner FW, Miller JM. Classification, identification, and clinical significance of Proteus, Providencia and Morganella. Clin Microbiol Rev. 2000;13:534-46.
5. O'Hara CM, Brenner FW, Steigerwalt AG, Hill BC, Holmes B, Grimont PAD, et al. Classification of Proteus vulgaris biogroup 3 with recognition of Proteus hauseri sp. nov., genomospecies 4, 5 and 6. Int J Syst Evol Microbiol. 2000;50:1869-75.
6. Kwil I, Dziadek J, Babicka D, Cierniewska-Cieslak A, Rozalski A. Use of randomly amplified polymorphic DNA (RAPD) analysis for identification of Proteus penneri. Adv Exp Med Biol. 2000;485:321-4.
7. Szabo D, Paterson DL. Proteus species. En: Yu VL, Weber R, Raoult D, editors. Antimicrobial therapy and vaccines. Volume I. Microbes. Maryland: Apple Trees Productions; 2002. p. 537-44.
8. Schneider R, Lockatell CV, Johnson D, Belas R. Detection and mutation of a luxS-encoded autoinducer in Proteus mirabilis. Microbiology. 2002;148:773-82.
9. Fallon D, Andrews N, Frodsham D, Gee B, Howe S, Iliffe A, et al. A comparison of the performance of cystine lactose electrolyte deficient (CLED) agar with Oxoid chromogenic urinary tract infection (CUTI) medium for the isolation and presumptive identification of organisms from urine. J Clin Pathol. 2002;55:524-9.
10. O'Hara CM. Evaluation of the Phoenix 100 ID/AST System and NID Panel for identification of Enterobacteriaceae, Vibronaceae, and commonly isolated nonenteric Gram-negative bacilli. J Clin Microbiol. 2006;44:928-33.
11. Rodríguez C, Radice M, Perazzi B, Castro S, Juárez J, Santini P, et al. Resistencia enzimática a betalactámicos en el género Proteus y evaluación de los fenotipos y genotipos de resistencia a cefalosporinas de tercera y cuarta generación en Proteus mirabilis. Enferm Infecc Microbiol Clin. 2005;23:122-6.
12. Rozalski A, Sidorczyk Z, Kotelko K. Potential virulence factors of Proteus bacilli. Microbiol Mol Biol Rev. 1997;61:65-89.
13. Mobley HL, Jones BD, Penner JL. Urease activity of Proteus penneri. J Clin Microbiol. 1987;25:2302-5.
14. Serwecinska L, Pytlos M, Lukomski S, Jaworski A, Rozalski A. The simultaneous production of both Hly- and Hpm-like hemolysins is characteristic of the Proteus penneri species. J Basic Microbiol. 1997;37:361-70.
15. Costas M, Holmes B, Frith KA, Idle C, Hawkey PM. Identification and typing of Proteus penneri and Proteus vulgaris biogroups 2 and 3, from clinical sources, by computerized analysis of electrophoretic protein patterns. J Appl Bacteriol. 1993;75:489-98.
16. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother. 1995;39:1211-33.
17. Datz M, Joris B, Azab EA, Galleni M, Van Beeumen J, Frere JM, et al. A common system controls the induction of very different genes. The class-A beta-lactamase of Proteus vulgaris and the enterobacterial class-C beta-lactamase. Eur J Biochem. 1994;226:149-57.
18. Péduzzi J, Reynaud A, Baron P, Barthélémy M, Labia R. Chromosomally encoded cephalosporin-hydrolyzing beta-lactamase of Proteus vulgaris RO104 belongs to Ambler's class A. Biochim Biophys Acta. 1994;1207:31-9.
19. Lukomski S, Pytlos M, Serwecinska L, Sidorczyk Z, Jaworski A. Analysis of antibiotic resistance determinants in Proteus penneri. Eur J Clin Microbiol Infect Dis. 1993;12:467-9.
20. Stock I. Natural antibiotic susceptibility of Proteus spp., with special reference to P. mirabilis and P. penneri strains. J Chemother. 2003;15:12-26.
21. Bonnet R. Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother. 2004;48:1-14.
22. Liassine N, Madec S, Ninet B, Metral C, Fouchereau-Peron M, Labia R, et al. Postneurosurgical meningitis due to Proteus penneri with selection of a ceftriaxone-resistant isolate: analysis of chromosomal class A beta-lactamase HugA and its LysR-type regulatory protein HugR. Antimicrob Agents Chemother. 2002;46:216-9.
23. Roberts MC. Update on acquired tetracycline resistance genes. FEMS Microbiol Lett. 2005;245:195-203.
24. Chopra I. New developments in tetracycline antibiotics: glycylcyclines and tetracycline efflux pump inhibitors. Drug Resist Updat. 2002;5:119-25.
25. Weigel LM, Anderson GJ, Tenover FC. DNA gyrase and topoisomerase IV mutations associated with fluoroquinolone resistance in Proteus mirabilis. Antimicrob Agents Chemother. 2002;46:2582-7.